Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 6.92%9.42B | 7.70%2.99B | 12.80%2.06B | 3.05%2.39B | 4.87%1.98B | 4.90%8.81B | 8.90%2.78B | 4.73%1.82B | 9.34%2.32B | -4.86%1.89B |
Operating revenue | 6.92%9.42B | 7.70%2.99B | 12.80%2.06B | 3.05%2.39B | 4.87%1.98B | 4.90%8.81B | 8.90%2.78B | 4.73%1.82B | 9.34%2.32B | -4.86%1.89B |
Cost of revenue | 0.39%4.94B | 2.45%1.54B | 7.80%1.08B | -4.28%1.28B | -3.66%1.03B | -1.19%4.92B | 5.10%1.51B | 1.36%1B | 0.49%1.33B | -12.44%1.07B |
Gross profit | 15.18%4.49B | 13.90%1.45B | 18.92%974.53M | 12.96%1.11B | 16.10%946.27M | 13.74%3.9B | 13.76%1.27B | 9.17%819.49M | 24.11%986.46M | 7.37%815.08M |
Operating expense | 12.98%4.59B | 11.24%1.37B | 14.01%1.09B | 10.77%1.13B | 16.98%1B | 20.37%4.07B | 25.41%1.23B | 22.95%955.2M | 25.02%1.02B | 6.93%855.71M |
Selling and administrative expenses | 11.26%4.1B | 10.00%1.23B | 14.70%977.17M | 6.32%1.02B | 15.51%873.13M | 20.98%3.68B | 27.51%1.12B | 21.69%851.98M | 25.78%955.94M | 7.00%755.91M |
-Selling and marketing expense | 19.50%3.38B | 16.70%1.04B | 25.58%800.56M | 19.57%844.7M | 17.10%694.04M | 5.78%2.83B | 13.29%892.4M | 5.82%637.49M | 5.70%706.44M | -3.77%592.69M |
-General and administrative expense | -15.98%719.16M | -16.12%191.82M | -17.66%176.61M | -31.21%171.64M | 9.72%179.09M | 130.41%855.91M | 149.92%228.7M | 119.57%214.49M | 172.07%249.5M | 80.21%163.23M |
Other operating expenses | 29.60%494.84M | 23.64%138.31M | 8.35%111.84M | 74.42%116.78M | 28.18%127.92M | 14.78%381.84M | 7.58%111.87M | 34.48%103.22M | 15.16%66.95M | 6.40%99.8M |
Operating profit | 36.97%-107.89M | 92.61%80.14M | 15.64%-114.48M | 48.48%-18.77M | -34.83%-54.78M | -468.56%-171.17M | -69.68%41.61M | -416.88%-135.71M | -56.01%-36.44M | 1.31%-40.63M |
Net non-operating interest income expense | -26.99%29.77M | -13.83%8.68M | -55.88%5.86M | -40.52%6.26M | 30.02%8.97M | 467.26%40.77M | 35.63%10.07M | 1,171.51%13.28M | 262.62%10.52M | 163.77%6.9M |
Non-operating interest income | -16.27%68.75M | -6.20%18.3M | -40.39%14.59M | -17.70%16.7M | 7.40%19.17M | 79.22%82.11M | -7.43%19.51M | 188.34%24.47M | 176.56%20.29M | 100.08%17.85M |
Non-operating interest expense | -5.70%38.99M | 1.94%9.62M | -22.01%8.73M | 6.89%10.44M | -6.85%10.21M | -27.36%41.34M | -30.86%9.44M | 15.08%11.19M | -29.28%9.76M | -44.50%10.96M |
Other net income (expense) | 82.84%-14.86M | 112.55%5.7M | 86.10%-1.26M | -117.74%-2.1M | 60.82%-17.21M | 85.93%-86.63M | 88.01%-45.45M | 92.74%-9.08M | 128.33%11.81M | 37.32%-43.91M |
Gain on sale of security | 112.44%6.48M | 454.98%27.04M | 86.10%-1.26M | -124.48%-2.1M | 60.82%-17.21M | 89.83%-52.05M | 97.97%-7.62M | 46.72%-9.08M | 120.54%8.56M | 43.68%-43.91M |
Special income (charges) | 38.30%-21.34M | ---21.34M | ---- | ---- | ---- | 66.66%-34.58M | ---- | ---- | --3.25M | ---- |
-Less:Restructuring and merger&acquisition | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---3.25M | ---- |
-Less:Impairment of capital assets | -80.31%6.93M | --6.93M | ---- | ---- | ---- | 167.67%35.21M | ---- | ---- | ---- | ---- |
-Write off | --14.4M | --14.4M | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
-Gain on sale of business | --0 | --0 | ---- | ---- | ---- | 100.70%631K | ---- | ---- | ---- | ---- |
Income before tax | 57.15%-92.99M | 1,416.52%94.53M | 16.45%-109.89M | -3.62%-14.61M | 18.84%-63.02M | 62.60%-217.03M | 102.66%6.23M | 13.73%-131.51M | 80.29%-14.1M | 36.38%-77.65M |
Income tax | 72.78%20.74M | 377.87%28.44M | -1,054.21%-18.57M | 60.13%3.76M | 304.67%7.1M | -54.67%12M | -61.85%5.95M | -54.31%1.95M | -35.77%2.35M | -40.75%1.76M |
Earnings from equity interest net of tax | -494.34%-24.66M | -956.98%-23.93M | -150.19%-1.94M | -181.59%-3.62M | 2,054.46%4.83M | 274.37%6.25M | 65.56%-2.26M | 1,535.32%3.86M | 16.79%4.43M | 141.56%224K |
Net income | 37.88%-138.38M | 2,225.67%42.15M | 28.04%-93.26M | -82.97%-21.99M | 17.54%-65.29M | 63.50%-222.78M | 99.23%-1.98M | 17.44%-129.6M | 83.17%-12.02M | 36.94%-79.18M |
Net income continuous Operations | 37.88%-138.38M | 2,225.67%42.15M | 28.04%-93.26M | -82.97%-21.99M | 17.54%-65.29M | 63.50%-222.78M | 99.23%-1.98M | 17.44%-129.6M | 83.17%-12.02M | 36.94%-79.18M |
Minority interest income | -15.87%46.81M | -9.49%42.02M | -63.77%-5.19M | 7.75%8.63M | -69.23%1.35M | 29.66%55.65M | 66.91%46.43M | -126.66%-3.17M | 25.73%8.01M | 238.76%4.37M |
Net income attributable to the parent company | 33.48%-185.2M | 100.27%129K | 30.34%-88.07M | -52.89%-30.62M | 20.24%-66.64M | 57.38%-278.42M | 82.97%-48.41M | 25.12%-126.43M | 74.24%-20.03M | 31.74%-83.55M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 33.48%-185.2M | 100.27%129K | 30.34%-88.07M | -52.89%-30.62M | 20.24%-66.64M | 57.38%-278.42M | 82.97%-48.41M | 25.12%-126.43M | 74.24%-20.03M | 31.74%-83.55M |
Basic earnings per share | 33.97%-3.09 | 0 | 30.99%-1.47 | -54.55%-0.51 | 21.28%-1.11 | 56.18%-4.68 | 83.23%-0.81 | 26.04%-2.13 | 73.81%-0.33 | 24.19%-1.41 |
Diluted earnings per share | 33.97%-3.09 | 0 | 30.99%-1.47 | -54.55%-0.51 | 21.28%-1.11 | 56.18%-4.68 | 83.23%-0.81 | 26.04%-2.13 | 73.81%-0.33 | 24.19%-1.41 |
Dividend per share | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |